SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Suven Life to present clinical data at Neuroscience 2017

13 Nov 2017 Evaluate

Suven Life Sciences is participating and presenting positive Pre-clinical and Phase-1 clinical data of several advanced molecules from their portfolio of new chemical entities (NCEs) and the status of Phase 2 clinical trial of their lead compound SUVN-502 at Neuroscience 2017, organized by Society for Neuroscience being held at Washington DC, USA during 13-15 November 2017. These data presentations highlight Suven’s continued commitment to explore new treatment options addressing unmet medical need through novel mechanisms and targets.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.


Suven Life Sciences Share Price

195.90 -0.10 (-0.05%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×